-
1 Comment
Yuyu Pharma, Inc is currently in a long term uptrend where the price is trading 41.3% above its 200 day moving average.
From a valuation standpoint, the stock is 86.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Yuyu Pharma, Inc's total revenue rose by 0.7% to $25B since the same quarter in the previous year.
Its net income has dropped by 136.6% to $-497M since the same quarter in the previous year.
Finally, its free cash flow fell by 229.6% to $-3B since the same quarter in the previous year.
Based on the above factors, Yuyu Pharma, Inc gets an overall score of 3/5.
| ISIN | KR7000220004 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | KO |
| CurrencyCode | KRW |
| Beta | 0.55 |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 2.1% |
| Market Cap | 76B |
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000220.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
